

ForPatients

by Roche

Colorectal Cancer (CRC) Non-Small Cell Lung Cancer (NSCLC) Pancreatic
Adenocarcinoma Ovarian Neoplasms Renal Cell Carcinoma

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Trial Status
Terminated

Trial Runs In
1 Countries

Trial Identifier
NCT05769959 BP44068

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT05769959 BP44068
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
